Author: sugaradmin

Introduction and Objective: Sodium Glucose Cotransporter-2 Inhibitors, or SGLT2is, are an anti-hyperglycemic medication with indications for diabetes, HF and CKD. SGLT2i usage is associated with increased risk for diabetic ketoacidosis (DKA), and we conducted a retrospective analysis for patient quality improvement at our hospital system. Our findings indicate a relationship between demographic identity variables and […]

Introduction and Objective:Xist, a long non-coding RNA essential for X chromosome inactivation (XCI) in female mammals, ensures dosage compensation of X-linked genes. Beyond XCI, Xist is implicated in immunity, cell proliferation, and obesity, a major risk factor for type 2 diabetes (T2D). This study explores Xist’s role in metabolism using mouse models.Methods: We developed mouse […]

Introduction and Objective: DPNP is a debilitating diabetes complication affecting ~30% of people with type 1 (T1D) or type 2 (T2D) diabetes. Current therapies offer limited relief with frequent adverse effects highlighting the need for innovative approaches.Methods: PROGRESS was a phase 2b study evaluating the efficacy and safety of pilavapadin (LX9211), a non-opioid inhibitor of […]

Introduction and Objective: Type 2 diabetes (T2D) is a heterogeneous disease, with an extensive clinical diversity. While many classifications of T2D have been proposed in recent years, none incorporate inflammatory parameters, despite the critical role of inflammation in the pathogenesis of T2D. In this study, we aim to integrate circulating immune cells (CIC) characterization to […]

Introduction and Objective: Of the many complications of diabetes, cardiovascular disease (CVD) is one of the deadliest. In many studies, hyperglycemia has been shown to cause endothelial cell dysfunction. While there are numerous studies which elucidate the molecular mechanisms by which hyperglycemia affects the vasculature, few studies have investigated how hyperglycemia affects the mechanical function […]

Introduction and Objective: Persistence with the injectable glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide for weight management has been studied extensively, but drivers of persistence are not well characterized. We sought to identify predictors of persistence in a US real-world population.Methods: Adults (≥18 years old) who had a first claim for semaglutide for weight management (index […]

Introduction and Objective: With half the global population predicted to be obese by 2035, understanding the role of adiposity on obesity-associated comorbidities is critical. Adipose tissue (AT) inflammation negatively affects atherosclerosis, insulin resistance, and metabolic-associated fatty liver disease, but the mechanism behind interorgan signaling remains a mystery. Extracellular vesicles (EVs) deliver bioactive cargo to alter […]

Introduction and Objective: Tirzepatide (TZP), a dual GIP-R and GLP-1R agonist, has demonstrated outstanding efficacy in glycemic control and weight loss. Structural studies have demonstrated the binding mechanism between tirzepatide and the GLP-1R-wilt type (WT). However, since population studies have demonstrated multiple SNPs on the GLP-1R, the mechanisms of TZP binding to GLP-1R variants have […]

Introduction and Objective: We showed that genetic variability in the PPARA region influences the effectiveness of the PPAR-α agonist fenofibrate on CVD and diabetic retinopathy (DR) progression, even in subjects without atherogenic dyslipidemia. Evidence suggests that higher genetically determined PPARA expression (Genetic Score (eQtGS) of PPARA retinal expression) may contribute to greater fenofibrate benefit. Here, […]